Inflammation Markers

•	Differences in atherosclerotic plaque burden and morphology between type 1 and 2 diabetes as assessed by multislice computed tomography Djaberi R, Schuijf JD, Boersma E, et al Diabetes Care. 2009;32(8):1507-1512
•	Low-grade chronic inflammation in the relationship between insulin sensitivity and cardiovascular disease (RISC) population: associations with insulin resistance and cardiometabolic risk profile de Rooij SR, Nijpels G, Nilsson PM, et al, for the Relationship Between Insulin Sensitivity and Cardiovascular Disease (RISC) Investigators Diabetes Care. 2009;32(7):1295-1301
•	Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy. Stettler C, Witt N, Tapp RJ, et al Diabetes Care. 2009;32(6):1098-1100
•	Location of arterial stiffening differs in those with impaired fasting glucose versus diabetes: implications for left ventricular hypertrophy from the Multi-Ethnic Study of Atherosclerosis Rerkpattanapipat P, D'Agostino RB Jr, Link KM, et al ACC Abstracts of the 48th Scientific Session. 2009;58(4):946-953
•	Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study Herder C, Peltonen M, Koenig W, et al; for the Finnish Diabetes Prevention Study Diabetologia. 2009 Jan 8. [Epub ahead of print]
•	Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial Ogawa H, Nakayama M, Morimoto T, Uemura S, et al, for the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators JAMA. 2008;300(18):2134-2141
•	The prevention of progression of arterial disease and diabetes (POPADAD) trial Belch J, MacCuish, Campbell I, et al, for the Prevention of Progression of Arterial Disease and Diabetes Study Group BMJ. 2008;337:a1840
•	Overweight Latino children and adolescents have marked endothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance Caballero AE, Bousquet-Santos K, Robles-Osorio L, et al Diabetes Care. 2008;31(3):576-582
•	Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial Howard BV, Roman MJ, Devereux RB, et al JAMA. 2008;299(14):1678-1689
•	Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Derosa G, Fogari E, Cicero AF, et al Hypertens Res. 2007 May; 30(5): 387-94
•	Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension Park H, Hasegawa G, Obayashi H, et al Clin Chimica Acta.. 2006;374:129-134
•	Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF 2nd, Kullo IJ Am J Hypertension.. 2007;20:83-89
•	Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial Mazzone T, Meyer PM, Feinstein SB, et al JAMA. 2006;296:2572-2581
•	Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin Araki T, Emoto M, Teramura M, et al Metabolism. 2006;55:996-1001
•	The associations between physical activity, inflammation, and coagulation markers, in people with metabolic syndrome: the ATTICA study Pitsavos C, Panagiotakos DB, Chrysohoou C, Kavouras S, Stefanadis C Eur J Cardiovasc Prev Rehabil. 2005;12:151-158
•	Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism Game BA, Maldonado A, He L, Huang Y Atherosclerosis. 2005;178:249-256
•	Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial Esposito K, Marfella R, Ciotola M, et al JAMA. 2004;292:1440-1446
•	Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults Malik S, Wong ND, Franklin SS Circulation. 2004;110:1239-1244
•	Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus Esposito K, Giugliano D, Nappo F, Marfella R Circulation. 2004;110:214-219
•	Evidence for a potent antiinflammatory effect of rosiglitazone Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P J Clin Endocrinol Metab. 2004;89:2728-2735
•	Peroxisome Proliferator-Activated Receptor-Gamma: Therapeutic Target for Diseases Beyond Diabetes: Quo Vadis? Pershadsingh, H. A. Expert Opin Investig Drugs. 2004;13:215-228
•	Nitric Oxide, Oxidative Excess, and Vascular Complications of Diabetes Mellitus Endemann DH, Schiffrin EL Curr Hypertens Rep. 2004;6:85-89
•	Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women Hu FB, Meigs JB, Li TY, Rifai N, Manson JE Diabetes. 2004;53:693-700
•	Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial Jager J, Kooy A, Lehert P, et al J Intern Med. 2005;257:100-109
•	Site Specificity of Atherosclerosis. Site-Selective Responses to Atherosclerotic Modulators VanderLaan PA, Reardon CA, Getz GS Arterioscler Thromb Vasc Biol.. 2004;24:12-22
•	Inflammation and Glucose Intolerance: A Prospective Study of Gestational Diabetes Mellitus Sauk WM, Sauk J, Shah A, Smirnakis KV, et al ACC Abstracts of the 48th Scientific Session. 2004;27:21-27
•	Peroxisome Proliferator-Activated Receptor-g Ligands Inhibit TGF-ß1-Induced Fibronectin Expression in Glomerular Mesangial Cells Guo B, Koya D, Isona M, Sugimoto T, Kashiwagi A, Haneda M Diabetes. 2004;53:200-208
•	Lipoprotein Lipase Is a Gene for Insulin Resistance in Mexican Americans Goodarzi MO, Guo X, Taylor KD, et al Diabetes. 2004;53:214-220
•	Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells Calabró P, Willerson JT, Yeh ETH, et al Circulation. 2003;108:1930-1932
•	Fasting Plasma Leptin, Tumor Necrosis Factor- Receptor 2, and Monocyte Chemoattracting Protein 1 Concentration in a Population of Glucose-Tolerant and Glucose-Intolerant Women. Impact on Cardiovascular Mortality Piemonti L, Calori G, Mercalli A, et al Diabetes Care. 2003;26:2883-2889
•	Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, et al Diabetes Care. 2003;26:2588–2594
•	Minireview: Adiposity, Inflammation, and Atherogenesis Lyon CJ, Law RE, Hsueh WA Endocrinology. 2003;144:2195-2200
•	Insulin Resistance, Inflammation, and Serum Fatty Acid Composition Fernández-Real J-M, Broch M, Vendrell J, Ricart W Diabetes Care. 2003;26:1362-1368
•	Interleukin-6 Induces Cellular Insulin Resistance in Hepatocytes Senn JJ, Klover PJ, Nowak IA, Mooney RA Diabetes. 2002;51:3391-3399
•	Fasting Plasma Ghrelin Levels Are Negatively Correlated With Insulin Resistance and PAI-1, but Not With Leptin, in Obese Children and Adolescents Ikezaki A, HosodaH , Ito K, et al Diabetes. 2002;51:3408-3411
•	Prospective Study of C-Reactive Protein in Relation to the Development of Diabetes and Metabolic Syndrome in the Mexico City Diabetes Study Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM Diabetes Care. 2002;25:2016-2021
•	Increased Plasminogen Activator Inhibitor-1 Activity in Offspring of Type 2 Diabetic Patients

Clinical Bridges, Secaucus, NJ
Clinical Bridges is a division of KnowledgePoint360 Group, LLC.
Copyright © 2009 Clinical Bridges. All rights reserved.
National Diabetes Education Initiative, Clinical Bridges, and
KnowledgePoint360 are trademarks of KnowledgePoint360 Group, LLC.

Disclaimer Statement - Privacy Statement